COVID-19 is the pandemic that hit the world starting December 2019. Recent studies and international statistics have shown an increased prevalence, morbidity as well as mortality of this disease in male patients compared to female patients. The aim of this brief communication is to describe the pathophysiology of this sex-discrepancy, based on the infectivity mechanism of the coronavirus including the Angiotensin-Converting Enzyme 2 (ACE2), the Type II transmembrane Serine Protease (TMPRSS2), and the androgen receptor. This could help understand the susceptibility of urological patients, especially those receiving androgen deprivation therapy for prostate cancer, and testosterone replacement therapy. (C) 2020 Elsevier Masson SAS. All rights reserved.
Mjaess, G., Karam, A., Aoun, F., Albisinni, S., Roumeguere, T. (2020). COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor|COVID-19 et la susceptibilité du sexe masculin: le rôle de l'ACE2, la TMPRSS2 et le récepteur aux androgènes. PROGRES EN UROLOGIE, 30(10), 484-487 [10.1016/j.purol.2020.05.007].
COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor|COVID-19 et la susceptibilité du sexe masculin: le rôle de l'ACE2, la TMPRSS2 et le récepteur aux androgènes
Albisinni S.;
2020-01-01
Abstract
COVID-19 is the pandemic that hit the world starting December 2019. Recent studies and international statistics have shown an increased prevalence, morbidity as well as mortality of this disease in male patients compared to female patients. The aim of this brief communication is to describe the pathophysiology of this sex-discrepancy, based on the infectivity mechanism of the coronavirus including the Angiotensin-Converting Enzyme 2 (ACE2), the Type II transmembrane Serine Protease (TMPRSS2), and the androgen receptor. This could help understand the susceptibility of urological patients, especially those receiving androgen deprivation therapy for prostate cancer, and testosterone replacement therapy. (C) 2020 Elsevier Masson SAS. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
